Biogen today filed a Form 8-K with the United States Securities and Exchange Commission, disclosing that "On May 3, 2023, the European Commission notified Biogen Inc. of its decision that the period of regulatory market protection for Tecfidera extends until February 2, 2025.”
Biogen confirms that it has adequate capacity and supply of Tecfidera for patients in Europe through the period of its marketing protection and beyond.
